Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Fox Foundation (MJFF) Parkinsons Disease Research Exchange forum
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
Anyone considering these compounds should seek medical advice first and report any adverse reactions via the MHRA Yellow Card scheme
The subscription covers clinical care - including initial consultations and follow-up visits with clinicians trained in obesity medicine - plus access to in-app tracking tools, a lifestyle change program, health coaching, and a member community
The trial also showed that the combination produced dose-dependent, sustained weight loss without concerning additional adverse effects the side effect profile was broadly consistent with what would be expected from each individual agent
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
